Synonyms: BMS1001 | Example 1001 [WO2015160641A2]
Compound class:
Synthetic organic
|
|
Immunopharmacology Comments |
Small molecule checkpoint inhibitors are being developed as complementary and potentially synergistic therapeutics to the currently approved monoclonal antibodies used to inhibit the PD-1/PD-L1 checkpoint in immuo-oncology applications. Inhibitors of the PD-1/PD-L1 immune checkpoint functionally alleviate the PD-L1-induced exhaustion of T cells and re-instate effector cell-mediated tumour elimination, be they small molecules like BMS-1001 and BMS-1166 [2], or monoclonal antibodies like atezolizumab, durvalumab, pembrolizumab or nivolumab. |